Embecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In Favour

Embecta’s (NASDAQ: EMBC ) end market growth has a lot of moving parts, with the new technologies taking market share from EMBC’s product in insulin delivery and the increased use of GLP-1 drugs leading to less frequent use of EMBC’sI am a value focused investor, conducting fundamental research on sectors like but not limited to chemicals, homebuilders, building materials, industrials and metals & mining. I prefer to invest in stocks which are cheaply available and have a catalyst in the near future. My inve ...